Lantheus Holdings, Inc. Equity Securities, FV-NI, Gain (Loss)
Lantheus Holdings, Inc. (LNTH) reported Equity Securities, FV-NI, Gain (Loss) of -$9.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-08-06
- Lantheus Holdings, Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2026-06-30 was -$9.54M, a 165.44% decline year-over-year.
- Lantheus Holdings, Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was $14.90M.
- Lantheus Holdings, Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was -$9.49M.
- Lantheus Holdings, Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $1.16M, a 96.89% decline year-over-year.
- Lantheus Holdings, Inc. equity securities, fv-ni, gain (loss) for fiscal 2025 was -$8.62M.
- Lantheus Holdings, Inc. equity securities, fv-ni, gain (loss) for fiscal 2024 was -$43.56M.
- Lantheus Holdings, Inc. equity securities, fv-ni, gain (loss) for fiscal 2023 was $0.00.
- Lantheus Holdings, Inc. equity securities, fv-ni, gain (loss) for fiscal 2022 was $0.00.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.54M 10-Q · filed 2026-08-06 | $5.37M 10-Q · filed 2026-08-06 | -$4.12M derived: sum of 3 quarters · filed 2026-08-06 | -$2.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.90M 10-Q · filed 2026-05-07 | $5.42M derived: sum of 2 quarters · filed 2026-05-07 | $6.58M derived: sum of 3 quarters · filed 2026-05-07 | $21.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$9.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$8.33M derived: sum of 2 quarters · filed 2026-02-26 | $6.25M derived: sum of 3 quarters · filed 2026-08-06 | -$8.62M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.16M 10-Q · filed 2025-11-06 | $15.73M derived: sum of 2 quarters · filed 2026-08-06 | $871.00K 10-Q · filed 2025-11-06 | -$118.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $14.57M 10-Q · filed 2026-08-06 | -$289.00K 10-Q · filed 2026-08-06 | -$119.34M derived: sum of 3 quarters · filed 2026-08-06 | -$82.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$14.86M 10-Q · filed 2026-05-07 | -$133.92M derived: sum of 2 quarters · filed 2026-05-07 | -$96.59M derived: sum of 3 quarters · filed 2026-05-07 | -$119.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$119.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$81.73M derived: sum of 2 quarters · filed 2026-02-26 | -$104.27M derived: sum of 3 quarters · filed 2026-02-26 | -$43.56M 10-K · filed 2026-02-26 |
| 2024-09-30 | $37.33M 10-Q · filed 2025-11-06 | $14.79M derived: sum of 2 quarters · filed 2025-11-06 | $75.49M 10-Q · filed 2025-11-06 | $75.49M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$22.54M 10-Q · filed 2025-08-06 | $38.17M 10-Q · filed 2025-08-06 | $38.17M derived: sum of 3 quarters · filed 2026-02-26 | $38.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $60.70M 10-Q · filed 2025-05-07 | $60.70M derived: sum of 2 quarters · filed 2026-02-26 | $60.70M derived: sum of 3 quarters · filed 2026-02-26 | $60.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-07-31 | $0.00 10-Q · filed 2024-07-31 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |